Connecticut Teen In Remission from Hodgkin's

The Connecticut teenager known only as Cassandra C. who fought the state over receiving chemotherapy for her Hodgkin's lymphoma, is in remission.

This is according to sources familiar with the case, quoted by the Hartford Courant.

"We are very pleased with Cassandra's progress toward a complete recovery," said Department of Children and Families Commissioner Joette Katz in a statement. "We understand how difficult this has been for Cassandra and her family, but we have had full confidence throughout that the medical professionals involved in her treatment would be successful in saving her life."

Several physicians testified in front of the state Superior court last November and December that Cassandra stood an 85 percent chance of survival with chemotherapy, and that without it, she would die.

Following the testimony, the court granted the Department of Children and Families (DCF) temporary custody of the 17 year-old, who had earlier ran away to avoid continued chemotherapy treatments. In January, the state Supreme Court let the lower court's ruling stand.

She turns 18 in September, when she will be an adult and her medical choices will entirely be her own.

Source: Hartford Courant

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap